Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics, and platelet count in endotoxaemic pigs

Acta Anaesthesiologica Scandinavica

Volumn 44, Issue 1, 2000, Pages 24-31

  Eriksson, M ^a   Saldeen, T ^a   Mattsson, C ^b   Larsson, A ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Endotoxin; Hemodynamic; Melagatran; Platelet; Pulmonary; Septic shock; Thrombin; Tumor necrosis factor (TNF)

Indexed keywords

ANESTHETIC AGENT; ATROPINE; ESCHERICHIA COLI ENDOTOXIN; MELAGATRAN; MORPHINE; NITROUS OXIDE; PENTOBARBITAL; THROMBIN INHIBITOR; TILETAMINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; XYLAZINE; ZOLAZEPAM; ZOLETIL 100;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOTOXEMIA; FEMALE; GRAM NEGATIVE INFECTION; IMMUNE RESPONSE; LIVER FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; SWINE; THROMBOCYTE COUNT;

ANIMALS; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; ENDOTOXEMIA; FEMALE; FIBRIN; GLYCINE; HEMODYNAMIC PROCESSES; LIVER; MALE; PLATELET COUNT; SWINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033975739     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-6576.2000.440105.x     Document Type: Article

References (31)

1. 1. Verstraete M. Direct thrombin inhibitors: Appraisal of the antithrombotic/hemorrhagic balance. Thromb Haemost 1997: 78: 357-363.
2. 2. Hoffman M, Cooper ST. Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms. Blood Cells 1995: 21: 156-167.
3. 3. Nowak G, Markwardt F. Hirudin in disseminated intravascular coagulation. Haemostasis 1991: 1: 142-148.
4. 4. Close P, Bichler J, Kerry R, Ekman S, Bueller HR, Kienast J et al. Weak allergenicity of recombinant hirudin CGP 39393 group (HIT group). Coron Artery Dis 1994: 5: 943-949.
5. 5. Hewett JA, Roth RA. The coagulation system, but not circulating fibrinogen, contributes to liver injury in rats exposed to lipopolysaccharide from gram-negative bacteria. J Pharmacol Exp Ther 1995: 272: 53-62.
6. 6. Shibayama Y. Sinusoidal circulatory disturbance by microthrombosis as a cause of endotoxin-induced hepatic injury. J Pathol 1987: 151: 315-321.
7. 7. Chosay JG, Essani NA, Dunn CJ, Jaeschke H. Neutrophil margination and extravasation in sinusoids and venules of liver during endotoxin-induced injury. Am J Physiol 1997: 1: G1195-G1200.
8. 8. Pearson JM, Brown AP, Schultze AE, Ganey PE, Roth RA. Gadolinium chloride treatment attenuates hepatic platelet accumulation after lipopolysaccharide administration. Shock 1996: 5: 408-415.
9. 9. Myrvold HE, Brandberg Å, Lindquist O, Busch C, Lewis DH. The role of platelets and fibrinogen in experimental septic shock. Acta Chir Scand 1977:143: 131-137.
10. 10. Eriksson M, Larsson A, Saldeen T, Mattsson C. Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig. Thromb Haemost 1998: 80: 1022-1026.
11. 11. Modig J. Adult respiratory distress syndrome. Comp Pathol Bull 1989: 21: 2-4.
12. 12. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I et al. Effects of melagatran, a new low molecular weight thrombin inhibitor on thrombin and fibrinolytic enzymes. Thromb Haemost 1998: 79: 110-118.
13. 13. Vandermeer TJ, Menconi MJ, O'Sullivan BP, Larkin VA, Wang H, Kradin RL et al. Bactericidal/permeability-increasing protein ameliorates acute lung injury in porcine endotoxaemia. J Appl Physiol 1994: 76: 2006-2014.
14. 14. Goldsack NR, Chambers RC, Dabbagh K, Laurent GJ. Molecules in focus. Thrombin. Biochem Cell Biol 1998: 30: 641-646.
15. 15. Mehta JL, Chen L, Mattson C, Gustafson D, Saldeen TGP. Melagatran, an oral active site inhibitor of thrombin, prevents or delays formation of electrically-induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol 1998: 31: 345-351.
16. 16. Saldeen T. Pulmonary microembolism as a cause of acute respiratory failure. Ann Chir Gynaecol Suppl 1982: 196: 11-17.
17. 17. Eriksson M, Gerdin B, Saldeen T. Enhancement of the permeability-increasing effect of bradykinin and substance P by a peptide derived from fibrinogen. Int J Microcirc Clin Exp 1983: 2: 53-59.
18. 18. Hawker F. Liver dysfunction in critical illness. Anaesth Intensive Care 1991: 19: 165-181.
19. 19. Scott Conner CE, Grogan JB. The pathophysiology of biliary obstruction and its effect on phagocytic and immune function. J Surg Res 1994: 57: 316-336.
20. 20. Roelofsen H, van der Veere CN, Ottenhoff R, Schoemaker B, Jansen PLM, Oude Elferink RPJ. Decreased bilirubin transport in the perfused liver of endotoxaemic rats. Gastroenterology 1994: 107: 1075-1084.
21. 21. Bolder U, Jauch KW, Hofmann AF. Verminderter Transport von Gallensauren und organischen Anionen als Ursache der Cholestase bei Endotoxinämie. Langenbecks Arch Chir Suppl Kongressbd 1997: 114: 571-577.
22. 22. Decker K. Biologically active products of stimulated liver macrophages (Kupffer cells). Eur J Biochem 1990: 192: 245-261.
23. 23. Whiting JF, Green RM, Gollan JL. Tumor necrosis factor alfa decreases hepatocyte bile salt uptake and mediates endotoxin-induced cholestasis. Hepatology 1995: 22: 1273-1278.
24. 24. Greve JW, Gouma DJ, Buurman WA. Bile acids inhibit endotoxin-induced release of tumor necrosis factor by monocytes: an in vitro study. Hepatology 1989: 10: 454-458.
25. 25. Fujishima S, Aikawa N. Neutrophil-mediated tissue injury and its modulation. Intensive Care Med 1995: 21: 277-285.
26. 26. Shibayama Y, Asaka S, Urano T, Araki M, Oda K. Role of neutrophils and platelets in the pathogenesis of focal hepatocellular necrosis in endotoxaemia. Exp Toxicol Pathol 1995: 47: 35-39.
27. 27. Larsson A, Lundahl T, Eriksson M, Lundkvist K, Lindahl T. Endotoxin induced platelet microvesicle formation measured by flow cytometry. Platelets 1996: 7: 153-158.
28. 28. Hollenberg SM, Parrillo JE. Critical care medicine. JAMA 1996: 275: 1799-1800.
29. 29. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989: 321: 280-287.
30. 30. Taylor FB, Chang AC, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood 1998: 91: 1609-1615.
31. 31. Park CT, Creasey AA, Wright SD. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood 1997: 89: 4268-4274.